Abstract
Over 20% of patients who experience an out-of-hospital cardiac arrest (OHCA) present in a shockable rhythm, but anywhere from 2-28% of these individuals exhibit refractory ventricular fibrillation/ventricular tachycardia (VF/VT) and survival rates for refractory cases are low. The use of beta-blockade has become recognized as a novel therapy for refractory VF/VT, but no formal recommendations exist for its use. Several human studies evaluating this treatment modality have been conducted in recent years, thereby generating a need for a systematic review and meta-analysis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
